&nbsp;

ColonCancerFITCoverLetterKOH

New

Mar 2026

Document

ColonCancerFITCoverLetterKOH-FR

New

Mar 2026

Document

ColonCancerFITInstructionsKOH-FR

New

Mar 2026

Document

ColonCancerFITInstructionsKOH

New

Mar 2026

Regimen

CRBPPEME+PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Updated

Mar 2026

Regimen

CRBPPEME+PEMB

Cancer Type:

Gastrointestinal,

Mesothelioma (Peritoneal),

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Updated

Mar 2026

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Feb 2021

Regimen

CYBORD

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Mar 2026

Regimen

CYBORP

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2026

Regimen

CYBORD+DARA(SC)

Cancer Type:

Hematologic,

Amyloidosis

Intent: Palliative

Funding:

New Drug Funding Program

Daratumumab and Bortezomib in combo with Cyclophosphamide and Dexamethasone - Previously Untreated Light Chain (AL) Amyloidosis

ODB - General Benefit

cyclophosphamide - oral tablets

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (subcut),

Quick Link(s):

Regimen Monograph

Mar 2026

Regimen

CYBORD+DARA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma

ODB - General Benefit

cyclophosphamide - oral tablets

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2026

Regimen

CYBORD+DARA(SC)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma

ODB - General Benefit

cyclophosphamide - oral tablets

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (subcut),